2024
A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults
Kao C, Rostad C, Nolan L, Peters E, Kleinhenz J, Sherman J, Tippett A, Shih J, Yildirim I, Agbakoba V, Beresnev T, Ballou C, Kamidani S, Karmali V, Natrajan M, Scherer E, Rouphael N, Anderson E. A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults. The Journal Of Infectious Diseases 2024, 230: 1093-1101. PMID: 38536442, PMCID: PMC11565884, DOI: 10.1093/infdis/jiae148.Peer-Reviewed Original ResearchHealthy US adultsDouble-blindThird dosePlacebo-Controlled Clinical TrialSystemic reactionsHepatitis E virus vaccineUS adultsHepatitis E vaccinePlacebo groupPlacebo-controlledAdverse eventsE vaccineSecond doseClinical trialsDay 1Immune responseDosePhase 1ImmunogenicityMonthsSafety studiesVaccineInfant mortalityTrialsAdults
2020
The VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19
McAteer J, Yildirim I, Chahroudi A. The VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19. Clinical Infectious Diseases 2020, 71: 703-705. PMID: 32282038, PMCID: PMC7184475, DOI: 10.1093/cid/ciaa433.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Vaccines actCoronavirus 2Clinical trialsVaccine hesitancyVaccine candidatesNovel vaccinesCOVID-19COVID-19 pandemicVaccineTimes of COVID19PandemicTrials
2008
PIPERACILLIN/TAZOBACTAM PLUS AMIKACIN VERSUS CARBAPENEM MONOTHERAPY AS EMPIRICAL TREATMENT OF FEBRILE NEUTROPENIA IN CHILDHOOD HEMATOLOGICAL MALIGNANCIES
Yildirim I, Aytac S, Ceyhan M, Cetin M, Tuncer M, Cengiz AB, Secmeer G, Yetgin S. PIPERACILLIN/TAZOBACTAM PLUS AMIKACIN VERSUS CARBAPENEM MONOTHERAPY AS EMPIRICAL TREATMENT OF FEBRILE NEUTROPENIA IN CHILDHOOD HEMATOLOGICAL MALIGNANCIES. Pediatric Hematology And Oncology 2008, 25: 291-299. PMID: 18484473, DOI: 10.1080/08880010802016847.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAmikacinAnti-Bacterial AgentsBacteriaBacterial InfectionsCarbapenemsChildChild, PreschoolDrug Therapy, CombinationEnzyme InhibitorsFemaleHumansLeukemia, Myeloid, AcuteMaleNeutropeniaPenicillanic AcidPiperacillinPiperacillin, Tazobactam Drug CombinationPrecursor Cell Lymphoblastic Leukemia-LymphomaConceptsFebrile neutropenic episodesDuration of feverPiperacillin/tazobactamCarbapenem monotherapyNeutropenic episodesHematological malignanciesFebrile neutropeniaEmpirical treatmentInitial empirical regimenInfection-related mortalityPediatric hematological malignanciesChildhood hematological malignanciesAcute lymphoblastic leukemiaAcute myeloblastic leukemiaAmikacin combinationEmpirical regimenPTA groupCarbapenem groupLymphoblastic leukemiaTreatment modificationAntimicrobial therapyClinical trialsTreatment successAdditional antibioticsCommon cause